Strados Labs
Strados Labs develops the RESP™ Biosensor, an FDA-cleared device that remotely and continuously monitors lung sounds and events such as cough and wheeze, providing valuable data for clinical trials and patient care.
Strados Labs Services
Strados Labs provides remote respiratory monitoring solutions using their RESP™ Biosensor. The device allows clinicians and researchers to remotely and continuously monitor lung sounds and events such as cough and wheeze. This non-invasive, lightweight, and discreet device integrates noise filtering and encryption features for secure and accurate monitoring. It aids in demonstrating treatment efficacy in clinical trials and offers remote monitoring for at-risk cardiopulmonary patients.
RESP™ Biosensor Products
Strados Labs' primary product, the RESP™ Biosensor, is an FDA-cleared device that captures lung sounds, including coughing, wheezing, rhonchi, and other adventitious breathing sounds over time. Additional features include CoughCheck™ and WheezeCheck™ algorithms for real-time event detection, paired smartphone data transfer for quick access, and compatibility with both Android and iOS devices. The device is HIPAA compliant, employs end-to-end encryption, and advanced noise filtering to ensure patient data privacy and accuracy.
Clinical Trials and Research
Strados Labs actively participates in clinical trials to validate their RESP™ Biosensor. Notably, a 2019 study with NYC Health + Hospitals showed the device's superior ability to capture comprehensive respiratory data. They have also partnered with Ann & Robert H. Lurie Children’s Hospital of Chicago for evaluating the efficacy of the RESP™ Biosensor in children with wheeze. The device has been employed in clinical trials across four continents, measuring endpoints for various respiratory and cardiopulmonary conditions including chronic cough, IPF, bronchitis, COPD, asthma, RSV, Covid-19, and heart failure.
Technological Innovations
Strados Labs' RESP™ Biosensor integrates several advanced technological features. It captures multi-modal data and differentiates between subject and external coughs. The device records 24-hour cough frequency, intensity, and lung sounds related to activities, drugs, and devices. Its capabilities extend beyond simple monitoring to include analyzing lung sound recordings for a comprehensive understanding of patient health. The synchronization of recorded patient data via Bluetooth to mobile devices ensures fast and secure transfer of sensitive information.
Awards and Recognitions
Strados Labs has earned industry recognition for their innovative health technology. They were recognized as a quarterfinalist for the 2023 Digital Health Awards by the Digital Health Hub Foundation. The consistent focus on developing an FDA-cleared, HIPAA and GDPR-compliant device like the RESP™ Biosensor highlights their commitment to advancing digital health technologies.